Targeted Partnering & Licensing Summit Asia: Global Exposure, Local Advantage in Tokyo
Friday, February 27, 2026
The **Targeted Partnering & Licensing Summit Asia** is a pivotal event for the Asia-Pacific biopharma sector, scheduled for **February 26-27, 2026**, at The Westin Tokyo. This summit brings together industry leaders, investors, and innovators to explore strategic partnerships and licensing opportunities in advanced therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, T-cell engagers (TCEs), targeted protein degraders (TPD/PROTACs), and radiopharmaceuticals. As Asia emerges as a hotspot for clinical development due to its favorable infrastructure and cost efficiencies, Western pharma companies are increasingly seeking in-licensing deals and collaborations with local biotechs to bolster their pipelines.
Grace Robertson, Co-Founder of the Partnering & Licensing Summits at Hanson Wade, emphasized the summit's role in fostering non-dilutive capital through collaborations. She highlighted the potential to address challenges like ADC resistance, expand T-cell engager applications, develop novel PROTACs or molecular glues degraders (MGDs), and validate radioligand therapies. The event's format is designed to maximize networking efficiency, with 100% alignment across research focuses, business needs, and attendee responsibilities. Key highlights include a global pharma business development panel discussing in-licensing priorities, an Asia investors networking session to gauge investment enthusiasm, and an informal drinks reception for building relationships.
Attendees will gain access to high-value, de-risked early clinical programs with strong licensing potential. The summit facilitates connections with decision-makers from innovative biotechs and multinational pharma (MNC) companies, providing market intelligence on Asia's deal-making landscape. This includes insights into geographic carve-outs, milestone-based structures, and strategic co-development agreements. Recent industry reports underscore the surge in high-value ADC and bispecific licensing deals in China, alongside growing interest in TCRs and TPD programs as next-generation modalities offering superior precision and potency.
The **Strategy** category alignment is evident in how the summit positions Asia as a bridge between global exposure and local advantages. For pharma executives and business development leaders, this event represents a prime opportunity to secure funds for clinical advancement without equity dilution. Biopharma innovators can showcase assets to potential partners, while investors explore promising pipelines. The focus on targeted oncology and immunology reflects broader **Research & Development** trends, where Asia's clinical trial ecosystem is attracting global attention.
In the context of **Bio Pharma** innovations, discussions will cover cutting-edge modalities like radiopharmaceuticals, which are gaining traction for their targeted efficacy. **Manufacturing** considerations, such as scalable production for complex biologics, may also feature in panels. The summit's emphasis on in-person networking post-pandemic underscores its role in **Industry Updates**, including events that drive partnerships. Registration is open, urging early participation to leverage these opportunities.
This summit not only catalyzes deals but also shapes executive-level strategies for Asia's biopharma landscape. With Asia's regulatory evolution and investment influx, events like this are instrumental in accelerating therapy development. Participants can expect actionable insights into deal structures, investor sentiments, and pipeline gaps, making it indispensable for stakeholders in **Clinical Trials** and **Information Technology** integration for drug discovery. Overall, the Targeted Partnering & Licensing Summit Asia reinforces Tokyo's status as a hub for life sciences collaboration, promising tangible outcomes for attendees.
Expanding on the event's impact, the summit builds on successful U.S. iterations, tailoring content to Asia's unique dynamics. For drug manufacturers, it's a platform to discuss supply chain synergies in biologics production. **Expert Corner** sessions from global pharma leaders will provide strategic foresight. As partnerships proliferate, this event could herald a new wave of Asia-led innovations reaching global markets, enhancing competitiveness in the biopharma arena.
